Core Viewpoint - The company has announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 13.00 yuan per 10 shares, with no capital reserve transfer or bonus shares [1][2]. Profit Distribution Plan - The profit distribution is based on the total share capital minus the shares held in the company's repurchase account as of the record date [1][2]. - The total number of shares as of July 31, 2025, is 123,262,117, with the repurchase account holding a certain number of shares, leading to a proposed total cash dividend of 157,408,999.80 yuan (including tax) [2][3]. - The cash dividend represents 50.03% of the net profit attributable to shareholders for the first half of 2025 [2]. Decision-Making Process - The profit distribution plan has been authorized by the 2024 annual general meeting and approved by the board of directors with unanimous consent [3]. - The supervisory board has expressed that the profit distribution plan considers the company's normal operations and long-term development, ensuring no harm to minority shareholders [3]. - There is no need for further shareholder meeting approval for the implementation of the profit distribution plan [3].

证券代码：688016 证券简称：心脉医疗 公告编号：2025-031 上海微创心脉医疗科技（集团）股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会召开情况 上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"）第三届监 事会第七次会议（以下简称"本次会议"或"会议"）于2025年8月26日在公司会议 室以现场表决与通讯结合的方式在公司会议室召开。本次会议通知及相关资料已 于2025年8月15日以通讯方式送达全体监事。本次会议由公司监事会主席梁敏女 士召集并主持，会议应出席监事3名，实际出席监事3名。本次会议的召集、召开 方式符合相关法律、行政法规、部门规章、规范性文件和《上海微创心脉医疗科 技（集团）股份有限公司章程》（以下简称"《公司章程》"）的规定，会议决 议合法、有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： （一）审议通过《公司2025年半年度报告及其摘要》 监事会对公司2025年半年度报告及其摘要进行审核并发表书面意见，监事 ...

Core Points - The report details the fundraising and usage of funds by Shanghai MicroPort MedBot (Group) Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations [1][10] - The company raised a total of RMB 832.14 million from its initial public offering (IPO) in 2019 and RMB 1.81 billion from a subsequent issuance to specific investors in 2022 [1][10] - As of June 30, 2025, the remaining balance of the funds raised from the IPO was RMB 25.49 million, while the balance from the 2022 issuance was RMB 1.17 billion [1][10] Fundraising Overview - The company issued 18 million shares at RMB 46.23 per share in 2019, raising RMB 832,140,000, with a net amount of RMB 729,658,867.93 after deducting issuance costs [1][10] - In 2022, the company issued 10,748,106 shares at RMB 168.33 per share, raising RMB 1,809,228,682.98, with a net amount after costs not specified [1][10] Fund Usage and Balance - As of June 30, 2025, the company had used RMB 166,937.06 from the IPO funds, primarily for the development of medical devices [1][10] - The remaining balance of the IPO funds was RMB 25,494,864.34, while the 2022 issuance funds had a balance of RMB 1,174,150,962.83 after using RMB 89,446,375.42 during the reporting period [1][10] Fund Management - The company has established a dedicated fund management system to ensure that the raised funds are used appropriately and in compliance with regulations [1][10] - The funds are stored in special accounts, and the company has adhered to strict approval procedures for fund usage [1][10] Project Updates - The company has not reported any early investments or replacements of funds for the projects during the reporting period [1][10] - There were no instances of using idle funds for temporary working capital during this period [1][10] Future Plans - The company plans to extend the construction period for the "Global Headquarters and Innovation and Industrialization Base Project" to September 2027 due to various construction challenges [1][10][12]

Group 1 - The company has decided to abolish the supervisory board and amend its articles of association, with the audit committee of the board taking over the supervisory functions as per the Company Law [1][2] - The decision to cancel the supervisory board was approved in the eighth meeting of the third board of directors held on August 26, 2025, and will be submitted for approval at the first extraordinary general meeting of shareholders in 2025 [1][2] - The company will revise its articles of association and handle the necessary business registration changes, which will also require approval from the shareholders' meeting [2] Group 2 - The company plans to revise and add certain management systems in accordance with the latest regulations and its actual situation, with some requiring shareholder approval [2] - The revised management systems include regulations on the management of shares held by directors and senior management, which have been approved by the board but require shareholder approval to take effect [2] Group 3 - The company will disclose the revised articles of association and management systems on the Shanghai Stock Exchange website [2][3] - The amendments to the articles of association include changes to the roles and responsibilities of the legal representative and the management of company assets [3][4]

Core Viewpoint - The report evaluates the implementation and effects of the company's "Quality Improvement and Efficiency Enhancement" action plan for 2025, emphasizing the focus on enhancing operational efficiency, market competitiveness, and investor returns while navigating challenges in revenue and costs [1][2][3]. Group 1: Financial Performance - The company achieved total operating revenue of 714.43 million yuan, a decrease of 9.24% compared to the same period last year [1]. - Operating costs increased by 19.37% to 220.13 million yuan, while sales and management expenses rose by 53.68% and 32.00%, respectively, primarily due to the expansion of the overseas sales team following the acquisition of Lombard [1]. - The company reported an operating profit of 367.11 million yuan, down 22.35%, and a net profit attributable to shareholders of 314.65 million yuan, a decrease of 22.03% year-on-year [1]. Group 2: Product Development and Market Expansion - The company focuses on continuous product innovation, with significant R&D investments leading to the approval of several innovative products, including the Aortic Stent Graft System and the HepaFlow Tips [1][2]. - As of June 30, 2025, the company had submitted 741 patent applications, with 252 patents granted, including 89 domestic invention patents [2]. - International sales revenue reached 123 million yuan, a year-on-year increase of 95.22%, accounting for 17.25% of total revenue, with products sold in 45 countries and regions [3][4]. Group 3: Investor Returns and Governance - The company emphasizes shareholder returns, having distributed a total of 629.66 million yuan in cash dividends since its listing, with a proposed cash dividend of 1.30 yuan per share for 2025 [4][5]. - The total amount of cash dividends and share buybacks for 2024 reached 365.81 million yuan, representing 72.86% of the net profit attributable to shareholders [4]. - The company is committed to enhancing its governance structure and internal control systems to ensure compliance and protect shareholder rights [6][7]. Group 4: Communication and Investor Relations - The company maintains a strong commitment to information disclosure and investor communication, utilizing various channels to engage with investors and provide insights into its operations and strategies [6][7]. - The management team actively participates in investor meetings and events to enhance transparency and build trust with stakeholders [6][7].

Core Viewpoint - The company will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, to discuss its operational results and financial status with investors [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 17, 2025, from 15:00 to 17:00 [2][3]. - The location of the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][3]. - The format of the meeting will be an online interactive session [2][3]. Group 2: Participation Information - Investors can participate in the meeting by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [3]. - Investors are encouraged to submit questions from September 10 to September 16, 2025, via the designated email or the online platform [3]. - The company will address commonly asked questions during the briefing [3]. Group 3: Attendees - Key attendees include Dr. Zhu Qing (CEO), Mr. Ye Xiaojie (Independent Director), Mr. Liu Hao (VP of Treatment Solutions), Mr. Qiu Genyong (Secretary of the Board), and Ms. Li Chunfang (Senior Financial Director) [2].

二零二五年八月 股份有限公司 独立董事工作制度 上海微创心脉医疗科技（集团） 上海微创心脉医疗科技（集团）股份有限公司 独立董事工作制度 第三条 独立董事对公司及全体股东负有忠实与勤勉的义务，并应当按照相 关法律法规、本制度和公司章程的要求，认真履行职务, 在董事会中发挥参与决 策、监督制衡、专业咨询作用，维护公司整体利益，尤其要关注中小股东的合法 权益不受损害。 第四条 独立董事应当独立公正地履行职责，不受公司主要股东、或者其他 与公司存在利害关系的单位或个人的影响。 第五条 公司董事会设立独立董事,公司独立董事的人数应不少于公司董事 会人数的 1/3；担任公司独立董事的人员中，应至少包括 1 名会计专业人士。 以会计专业人士身份被提名为独立董事候选人的，应具备较丰富的会计专业 知识和经验，并至少符合下列条件之一： （一）具有注册会计师执业资格； （二）具有会计、审计或者财务管理专业的高级职称、副教授职称或者博士 学位； 第一章 总 则 第一条 为进一步完善上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）的法人治理结构，促进公司规范运作，根据《上市公司治理准则》、 《上海证券交易所科创板股票上 ...

Core Points - The article outlines the fundraising management system of Shanghai MicroPort CardioMed Technology (Group) Co., Ltd, aiming to enhance the safety and efficiency of fund usage while protecting investors' rights [2][21] - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2] Fundraising Management - The company defines fundraising as funds raised through the issuance of securities to unspecified or specific objects, excluding funds raised for equity incentive plans [2] - Upon receipt of funds, the company must promptly conduct verification procedures and ensure that funds are stored in a designated account approved by the board of directors [4][6] - The board of directors is responsible for the management and usage of the raised funds, with oversight from the audit committee and sponsor institutions [2][3] Fund Storage - Funds must be stored in a special account dedicated to fundraising, and cannot be used for other purposes [4][6] - A tripartite supervision agreement must be signed with the sponsor institution and the commercial bank within one month of the funds being received [6] Fund Usage - The company must use the raised funds in accordance with the approved investment plans and must disclose any significant deviations from these plans [9][10] - If a project cannot be completed within the original timeframe, the company must disclose the reasons and the current status of the funds [10][11] - The company is prohibited from using the funds for financial investments or providing them to controlling shareholders for improper benefits [12][13] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed to shareholders [20][21] - The company must conduct feasibility analyses for new investment projects and ensure that they align with the main business operations [22][23] Oversight and Reporting - The company is required to regularly disclose the status of fund usage and any changes in investment plans in its annual and semi-annual reports [16][20] - The sponsor institution or independent financial advisor must conduct ongoing supervision and report any irregularities to the Shanghai Stock Exchange [16][17]

上海微创心脉医疗科技（集团） 股份有限公司 对外投资管理制度 二零二五年八月 第一章 总 则 第一条 为规范上海微创心脉医疗科技（集团）股份有限公司（以下简称 "公司"）的重大经营及投资决策程序，建立系统完善的重大经营及投资决策机 制，确保决策的科学、规范、透明，有效防范各种风险，保障公司和股东的利益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行政法规、 规范性文件及《上海微创心脉医疗科技（集团）股份有限公司章程》（以下简称 "《公司章程》"），并参照中国证监会及证券交易所的相关规定，结合公司的 实际情况，特制定本制度。 第二条 重大经营与投资决策管理的原则： 第三条 公司实行股东会、董事会、总经理分层决策制度。 第四条 董事会、总经理、公司的高级管理人员及相关职能部门均应严格 遵守《公司法》及其他法律、行政法规、规范性文件和《公司章程》及本制度中 关于重大经营与投资决策及管理的各项规定，科学、合理地决策和实施公司有关 重大经营与投资事宜。 第二章 决策范围 第五条 根据本制度进行决策的经营投资事项包括： 上述购买或者出售资产，不包括购买原材料、燃料和动力，以及出售产品或 商品等与日常经 ...

上海微创心脉医疗科技（集团） 股份有限公司 融资与对外担保制度 二零二五年八月 上海微创心脉医疗科技（集团）股份有限公司 融资与对外担保制度 第一章 总则 第一条 为了规范上海微创心脉医疗科技（集团）股份有限公司（以下简称 "公司"）的融资与对外担保行为，有效控制公司融资风险和担保风险，保护 公司财务安全和投资者的合法权益，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所科创板股票上市规则》、《上市公司监管指引第8号——上市 公司资金往来、对外担保的监管要求》等相关法律、法规的规定及《上海微创 心脉医疗科技（集团）股份有限公司章程》（以下简称"《公司章程》"）之 规定，并结合公司实际情况，特制订本管理制度。 第二条 本制度所称融资，是指公司向以银行为主的金融机构进行间接融资 的行为，主要包括综合授信、流动资金贷款、固定资产贷款、信用证融资、票 据融资和开具保函等形式。 公司直接股权融资行为不适用本制度。 第三条 本制度所称对外担保，是指公司为他人提供的担保，包括公司对控 股子公司的担保。 第四条 公司为自身债务提供担保不适用本制度 ...